Showing results (211-220 of 219) with videos related to
Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 219 results.
The Journal of Infectious Diseases|November 9, 2018
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and SenegalNavin Venkatraman, Birahim Pierre Ndiaye, Georgina Bowyer, et al.Lancet (London, England)|August 23, 2014
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trialRobert C Read, David Baxter, David R Chadwick, et al.The Lancet. Microbe|January 13, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection studyNavin Venkatraman, Daniel Silman, Duncan Bellamy, et al.Science (New York, N.Y.)|September 4, 2025
Resistin-like molecule γ attacks cardiomyocyte membranes and promotes ventricular tachycardiaNina Kumowski, Steffen Pabel, Jana Grune, et al.Clinical and Vaccine Immunology : CVI|December 26, 2014
Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNAFrank Struyf, Brigitte Colau, Cosette M Wheeler, et al.Nature Cardiovascular Research|August 29, 2022
Neutrophils incite and macrophages avert electrical storm after myocardial infarctionJana Grune, Andrew J M Lewis, Masahiro Yamazoe, et al.NPJ Vaccines|October 17, 2018
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.The Lancet. Microbe|January 13, 2025
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trialsNavin Venkatraman, Alfred B Tiono, Georgina Bowyer, et al.The Lancet. Oncology|June 14, 2015
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA TrialsAimée R Kreimer, Frank Struyf, Maria Rowena Del Rosario-Raymundo, et al.Pageof 22